News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Qualicaps is the third largest producer of hard capsules for oral dosage solutions
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
